| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 12.767 | 19.064 | 29.599 | 39.882 | 58.983 |
| Total Income - EUR | - | - | - | - | - | 12.767 | 19.064 | 29.599 | 54.034 | 58.984 |
| Total Expenses - EUR | - | - | - | - | - | 2.737 | 1.632 | 4.263 | 32.482 | 19.214 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 10.031 | 17.433 | 25.336 | 21.551 | 39.769 |
| Net Profit/Loss - EUR | - | - | - | - | - | 9.664 | 16.930 | 24.492 | 18.237 | 34.018 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Alemedobgyn S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 20.278 | 27.757 | 96.565 |
| Current Assets | - | - | - | - | - | 9.787 | 21.340 | 5.777 | 13.312 | 6.184 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 0 | 182 | 2.123 | 1.282 | 323 |
| Cash | - | - | - | - | - | 9.787 | 21.158 | 3.654 | 12.030 | 5.861 |
| Shareholders Funds | - | - | - | - | - | 9.706 | 20.962 | 25.241 | 39.459 | 73.257 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 82 | 378 | 814 | 1.609 | 29.492 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Alemedobgyn S.r.l.